Complaint
Peptide Semaglutide Tirzepatide Epitalon Selank Melanotan II Epithalon
Product name:Semaglutide
Cas No.:910463-68-2
Molecular formular: C187H291N45O59
Molecular weight : 4113.58
Purity: 98%
Appearance:White Crystalline Powder
Semaglutide is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insul.It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour. It can be used as both injection-type or oral-type drug.
Researchers at the University of Leeds reported in 2017 that it can also be used for the treatment of obesity. It reduces hunger, food craving and body fat.
Description of Liraglutide CAS 204656-20-2
| Product name | Liraglutide | |
| Appearance | white solid | |
| Purity | 99%min | |
| CAS No. | 204656-20-2 | |
| EINECS No. | 810-818-7 | |
| MF. | C172H265N43O51 | |
| Grade Standard | Medicine Grade | |
Introduction for Liraglutide CAS 204656-20-2
Liraglutide (NN2211) is a long-acting gluca on-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insuli secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxend as a treatment for obesity in adults with at least one weight-related comorbid condition.
Liraglutide was approved for treatment of type 2 diabetes by the European Medicines Agency (EMA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010. More recently, Liraglutide was approved by the FDA on December 23, 2014 for treatment for obesity in adults with some related comorbidity.
1. Glutamine Powder is the most prevalent amino acid in the bloodstream.
2. Glutamine Powder is involved in more metabolic processes than any other amino acid.
3. Glutamine Powder is converted to glucose when more glucose is required by the body as an energy source.
4. Glutamine Powder also plays a part in maintaining proper blood glucose levels and the right pH range.
5. Glutamine Powder serves as a source of fuel for cells lining the intestines. Without it, these cells waste away.
6. Glutamine Powder assists in maintaining the proper acid/alkaline balance in the body, and is the basis of the building
blocks for the synthesis of RNA and DNA.
| RFQ |
